Search company, investor...

Predict your next investment

Venture Capital
htgf.de

Investments

936

Portfolio Exits

117

Funds

4

Partners & Customers

1

About High-Tech Grunderfonds

High-Tech Grunderfonds (HTGF) is Germany's most active and leading seed-stage investor. The firm finances a technology-driven company – whether active in the fields of cleantech or robotics, developing new drugs, chemical processes, or new software: come profit from its experience and the extensive network of its team and its technological and entrepreneurial expertise.

Headquarters Location

Schlegelstrasse 2

Bonn, 53113,

Germany

+49 228-82300-100

Want to inform investors similar to High-Tech Grunderfonds about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing High-Tech Grunderfonds

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find High-Tech Grunderfonds in 1 Expert Collection, including Fitness Tech.

F

Fitness Tech

227 items

We define fitness tech as companies leveraging software and technology to augment approaches to developing or maintaining physical fitness. Companies in this category develop tools and services including workout apps, wearables, and connected fitness equipment.

Research containing High-Tech Grunderfonds

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned High-Tech Grunderfonds in 1 CB Insights research brief, most recently on Jul 1, 2020.

Latest High-Tech Grunderfonds News

High-Tech Gründerfonds Management GmbH. (11/17/22). "Press Release: FundaMental Pharma Launches with EUR 10 Million in Seed Fina...

Dec 3, 2022

Organisation   FundaMental Pharma GmbH (“FundaMental”), a preclinical neuroscience company spun out of Heidelberg University, today announces that it has launched with EUR 10 million in seed financing led by BioGeneration Ventures (BGV) and Thuja Capital, with participation from other investors, including coparion and High-Tech Gründerfonds (HTGF). Built on the pioneering research of Professor Hilmar Bading and Dr. Jing Yan published in Science[1], the founders of FundaMental have identified first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease. FundaMental’s novel approach relies on separating the normal neuroprotective effect of synaptic glutamate from its neurotoxic extra-synaptic actions, which are eliminated by the inhibitors. “I am convinced that the successful development of FundaMental’s small molecule inhibitors will mark a milestone in neuropharmacology and possibly beyond. It has been a privilege to have worked with Professor Bading`s team since 2010 and to have put together such a strong leadership team. Having found visionary investors whose aims are aligned with the founder’s goals of stopping neurodegeneration, this vision can now become reality after many years of dedication and persistence.” Dr. Thomas Schulze, CEO and co-founder of FundaMental “It is probably no exaggeration to call the discovery of the new therapeutic principle of ‘inhibition of an extra-synaptic glutamate-activated death signaling complex’ a breakthrough in neuroscience. These inhibitors have the potential to revolutionize therapies for currently untreatable neurodegenerative diseases and offer hope to many affected and suffering patients.” Professor Hilmar Bading, Director of the Department of Neurobiology and the Interdisciplinary Center for Neurosciences at Heidelberg University and Co-Founder of FundaMental In conjunction with the financing, FundaMental also announced several key senior management appointments as well as the Board of Directors of the company. Dr. Gabriele Hecker-Barth has joined as Chief Medical Officer and Dr. Jing Yan as Senior Director of Research. Dr. Keno Gutierrez of BGV and Dr. Michel Briejer of Thuja Capital, Professor Hilmar Bading and Dr. Thomas Schulze have been appointed to the company’s Board of Directors. “FundaMental’s novel therapeutics provide new hope to patients of ALS, Huntington’s disease and spinocerebellar ataxia 3, which remain devastating diseases that have an immense impact on the quality of patients’ lives. We are excited to invest and support the FundaMental team as they endeavor to make these molecules ready for the clinic.” Dr. Keno Gutierrez, new Chairman of FundaMental’s Board of Directors and Partner at BGV “Professor Bading and Dr. Yan have made a promising and important discovery, unlocking the possibility to inhibit glutamate neurotoxicity while leaving its physiologically important aspects unaffected. We are thrilled to be part of this venture with a mission to impact the lives of patients suffering from these neurodegenerative diseases.” Dr. Michel Briejer, Board Member and Managing Partner at Thuja Capital “The FundaMental Pharma team has achieved promising results with their interface inhibitors, which have the potential to open a new therapeutic window for the treatment of neurodegenerative diseases such as ALS. We are happy to have a consortium of reputable investors joining the company on its further journey towards success.” Niels Sharman, Investment Manager at HTGF About FundaMental Pharma GmbH FundaMental Pharma (“FundaMental”) is a neuroscience company, spun out of Heidelberg University, developing first-in-class small inhibitors for treatment of a range of neurodegenerative diseases. FundaMental scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. While FundaMental current focus is on Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease, the applicability of these molecules extend to a range of neurogenerative disorders such as dementia and aging-related memory loss. For more information, please visit: www.fundamentalpharma.com Contact About BGV BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies. The Company has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class companies. BGV manages over EUR 225 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together. BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realization for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. BGV is based in Naarden, The Netherlands. For more information, please visit: www.biogenerationventures.com Contact Email: info@biogeneration.vc About coparion coparion provides venture capital to accelerate momentum and growth. With a current fund of EUR 275 million coparion has the means to do so. coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the coparion team discerns potentials and opens up new perspectives. coparion only invests with co-investors. Investment focus is on German companies in the start-up and early growth phase. coparion is based in Cologne and Berlin. For more information, please visit www.coparion.vc. About High-Tech Gründerfonds The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported over 680 start-ups since 2005. With the launch of its fourth fund, HTGF now has over 1.3 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected more than 4 billion euros of capital into the HTGF portfolio via more than 1,900 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 160 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and the Fraunhofer-Gesellschaft along with over 40 companies from a wide range of industries. Press Contact +49 228 82300188

High-Tech Grunderfonds Investments

936 Investments

High-Tech Grunderfonds has made 936 investments. Their latest investment was in Maya as part of their Pre-Seed - II on February 2, 2023.

CBI Logo

High-Tech Grunderfonds Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/1/2023

Pre-Seed - II

Maya

$1.3M

Yes

Antler, High-Tech Grunderfonds, and Undisclosed Angel Investors

3

1/27/2023

Seed VC - II

C-mo Medical Solutions

$5.2M

No

2

1/26/2023

Seed VC

Refined Laser System

$2.94M

Yes

3

1/24/2023

Series A - II

Subscribe to see more

Subscribe to see more

10

1/16/2023

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/1/2023

1/27/2023

1/26/2023

1/24/2023

1/16/2023

Round

Pre-Seed - II

Seed VC - II

Seed VC

Series A - II

Seed VC

Company

Maya

C-mo Medical Solutions

Refined Laser System

Subscribe to see more

Subscribe to see more

Amount

$1.3M

$5.2M

$2.94M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Antler, High-Tech Grunderfonds, and Undisclosed Angel Investors

Sources

3

2

3

10

10

High-Tech Grunderfonds Portfolio Exits

117 Portfolio Exits

High-Tech Grunderfonds has 117 portfolio exits. Their latest portfolio exit was Humedics on January 04, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/4/2023

Acquired

$99M

3

11/9/2022

Acquired

$99M

8

10/20/2022

Acquired

$99M

1

9/13/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/28/2022

Shareholder Liquidity

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/4/2023

11/9/2022

10/20/2022

9/13/2022

6/28/2022

Exit

Acquired

Acquired

Acquired

Acquired

Shareholder Liquidity

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

8

1

10

10

High-Tech Grunderfonds Fund History

4 Fund Histories

High-Tech Grunderfonds has 4 funds, including High-Tech Gründerfonds IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/14/2022

High-Tech Gründerfonds IV

$420.5M

1

5/29/2018

High-Tech Gründerfonds III

$99M

10

4/11/2014

High-Tech Gründerfonds II

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2005

High-Tech Gruenderfonds I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

6/14/2022

5/29/2018

4/11/2014

12/31/2005

Fund

High-Tech Gründerfonds IV

High-Tech Gründerfonds III

High-Tech Gründerfonds II

High-Tech Gruenderfonds I

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$420.5M

$99M

$99M

$99M

Sources

1

10

10

10

High-Tech Grunderfonds Partners & Customers

1 Partners and customers

High-Tech Grunderfonds has 1 strategic partners and customers. High-Tech Grunderfonds recently partnered with Swiss Startup Capital Investors Club on October 10, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

10/15/2019

Partner

Switzerland

Swiss Startup Group and High-Tech Gründerfonds (HTGF) partner to invest in the most promising early stage Swiss and German Startups

Max Meister , CEO of the Swiss Startup Capital AG , comments : `` It 's an important next step for us to partner with High-Tech Gründerfonds , one of the most renown and active early stage Startup investors in Europe .

1

Date

10/15/2019

Type

Partner

Business Partner

Country

Switzerland

News Snippet

Swiss Startup Group and High-Tech Gründerfonds (HTGF) partner to invest in the most promising early stage Swiss and German Startups

Max Meister , CEO of the Swiss Startup Capital AG , comments : `` It 's an important next step for us to partner with High-Tech Gründerfonds , one of the most renown and active early stage Startup investors in Europe .

Sources

1

High-Tech Grunderfonds Team

6 Team Members

High-Tech Grunderfonds has 6 team members, including current Controller, Gisela van den Boom.

Name

Work History

Title

Status

Gisela van den Boom

Controller

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Gisela van den Boom

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Controller

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.